Drug Trial Radar · NCT02518139
A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)
Last checked: Nov 19, 2026Latest source record: Feb 24, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,060
Actual
Start
Sep 2015
Primary completion
Jun 2017
Study completion Jun 2017
Sponsor
- Lead sponsor
- Mylan Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Theravance Biopharma
- First posted
- Aug 7, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to measure the safety and tolerability of TD 4208, an investigational drug being developed to treat people with moderate to very severe COPD, compared to tiotropium.
Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
Interventions
TD-4208Drug
Subjects receiving TD-4208 are blinded to one of two doses of 4208.
TiotropiumDrug
There is not a placebo, there is an active comparator (Tiotropium) arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse Events: Frequency and SeverityTime frame: Baseline to Day 365
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Palmetto Medical Research Associates L.L.C
Easley, South Carolina
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.